UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 22, 2019
VITALITY BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-53832 | 75-3268988 | ||
(State
or other jurisdiction of incorporation) |
(Commission
File Number) |
(I.R.S.
Employer Identification No.) |
1901 Avenue of the Stars, 2nd Floor Los Angeles, California |
90067 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (530) 231-7800
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Director
Effective April 22, 2019, the Board of Directors (the “Board”) of Vitality Biopharma, Inc. (the “Company”) accepted Dr. Avtar Dhillon’s resignation from the Board. The size of the Board will remain at six (6) directors. The vacancy on the Board created by Dr. Dhillon’s resignation shall remain vacant until the Board identifies an appropriate candidate.
Item 7.01 | Regulation FD Disclosure. |
On April 25, 2019, the Company issued a press release announcing Dr. Dhillon’s resignation. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit | Description | |
99.1 | Press Release issued by the Company on April 25, 2019, furnished herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VITALITY BIOPHARMA, INC. | ||
Dated: April 25, 2019 | By: | /s/ Robert Brooke |
Name: | Robert Brooke | |
Title: | Chief Executive Officer |
EXHIBIT 99.1
Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors
LOS ANGELES, CA – (GLOBE NEWSWIRE – April 25, 2019) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Dr. Avtar Dhillon has decided to resign from its board of directors.
Dr. Dhillon was a co-founder of the Company along with Vitality’s current CEO Robert Brooke, and he has previously served as its Chairman and as a Director. He departs to focus on other professional interests including a senior management role with a licensed medical cannabis producer in Canada.
“It has been a pleasure for me to have been a co-founder of Vitality and to help build it to its current stage. Under its new leadership, including a strong board and management, I’m leaving the company in great hands,” said Dr. Dhillon. He added that, “Given the Company’s recent financing and the continued progress of its team, I remain very excited about Vitality’s growth potential.”
Vitality’s Chairman of the Board Edward Feighan accepted the resignation and stated, “Dr. Dhillon’s service on our Board has been extremely valuable and insightful. I know that I share the sentiments of our Board and senior management to state that his guidance and support have been critical to our success to date. The entire Vitality family is grateful for his leadership, and wishes him much success with his current and future ventures.”
About Vitality Biopharma (Ticker: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. The Company’s operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Contact | |
Vitality Biopharma | |
Investor Relations | |
info@vitality.bio | |
1-530-231-7800 | |
www.vitality.bio |